Table 2.
Biochemical Characteristics of patients of acromegaly with and without diabetes.
| Parameters | Acromegaly with diabetes (Group A) | Acromegaly without diabetes (Group B) | Controls (Group C) | P-value A vs. B |
P-value A vs. C |
P-value B vs. C |
|---|---|---|---|---|---|---|
| FPG (mg/dl) | 140.5 ± 7.4 | 99.1 ± 2.0 | 98.1 ± 1.2 | 0.0001*** | 0.0001*** | 0.913 |
| PPG (mg/dl) | 195.9 ± 15.6 | 138.6 ± 7.4 | – | 0.061 | ||
| HbA1c (%) | 7.8 ± 0.6 | 5.7 ± 0.1 | – | 0.001*** | ||
| GH-basal (ng/ml) | 66.3 ± 16.8 | 64.8 ± 26.6 | 0.6 ± 0.2 | 0.998 | 0.008** | 0.010** |
| IGF1 (ng/ml) | 778.0 ± 101.4 | 802.9 ± 68.7 | – | 0.185 | ||
| Nadir GH-OGTT (ng/ml) | 57.2 ± 14.7 | 47.6 ± 17.2 | – | 0.978 | ||
| Mean tumor volume (cm3) | 14.5 ± 3.2 | 12.2 ± 4.0 | – | 0.375 | ||
| TSH (μU/ml) | 1.06 ± 0.1 | 2.0 ± 1.1 | – | 0.090 | ||
| T4 (μg/dl) | 6.9 ± 0.5 | 7.2 ± 0.5 | – | 0.268 | ||
| LH (mU/ml) | 2.9 ± 1.0 | 6.7 ± 3.2 | – | 0.018* | ||
| FSH (mU/ml) | 2.6 ± 0.2 | 13.5 ± 7.0 | – | 0.002** | ||
| PRL (ng/ml) | 27.5 ± 6.0 | 21.5 ± 5.1 | – | 0.946 | ||
| F (nmol/l) | 172.1 ± 43.4 | 215.5 ± 21.2 | – | 0.017* | ||
| T (nmol/l) | 2.8 ± 0.5 | 5.2 ± 0.9 | – | 0.69 | ||
| E2 (pg/ml) | 4.6 ± 0.2 | 4.6 ± 0.2 | – | 0.59 |
One-way ANOVA test was applied to see the comparison among Group A, B and C. Post hoc analyses for multiple comparisons were performed for significant parameters in ANOVA test. To evaluate the effect of diabetes, independent ‘t’ test for comparison of continuous parametric parameters was applied.
FPG fasting plasma glucose, PPG post-prandial glucose, HbA1c glycated hemoglobin, GH growth hormone, IGF1 insulin like growth factor-1, GH-OGTT Nadir growth hormone after oral glucose tolerance test, TSH thyroid-stimulating hormone, T4 thyroxine, LH luteinizing hormone, FSH follicle stimulating hormone, PRL prolactin, T testosterone, E2 estradiol, F cortisol.
Data was expressed as mean ± S.E.M, *p < 0.05, **p < 0.01, ***p < 0.001.